4//SEC Filing
SYNAGEVA BIOPHARMA CORP 4
Accession 0001209191-15-055578
CIK 0000911326operating
Filed
Jun 22, 8:00 PM ET
Accepted
Jun 23, 10:37 AM ET
Size
27.3 KB
Accession
0001209191-15-055578
Insider Transaction Report
Form 4
Quart Barry D
Director
Transactions
- Disposition to Issuer
Stock Options (Right to Buy)
2015-06-22−1,375→ 0 totalExercise: $10.10Exp: 2019-07-21→ Common Stock (1,375 underlying) - Disposition to Issuer
Stock Options (Right to Buy)
2015-06-22−7,500→ 0 totalExercise: $80.35Exp: 2024-06-04→ Common Stock (7,500 underlying) - Disposition to Issuer
Stock Options (Right to Buy)
2015-06-22−3,750→ 0 totalExercise: $40.74Exp: 2022-06-27→ Common Stock (3,750 underlying) - Disposition to Issuer
Stock Options (Right to Buy)
2015-06-22−1,375→ 0 totalExercise: $20.60Exp: 2018-06-26→ Common Stock (1,375 underlying) - Disposition to Issuer
Stock Options (Right to Buy)
2015-06-22−1,000→ 0 totalExercise: $23.95Exp: 2017-06-27→ Common Stock (1,000 underlying) - Disposition to Issuer
Stock Options (Right to Buy)
2015-06-22−8,375→ 0 totalExercise: $23.00Exp: 2021-12-20→ Common Stock (8,375 underlying) - Disposition to Issuer
Stock Options (Right to Buy)
2015-06-22−5,001→ 0 totalExercise: $40.32Exp: 2023-06-06→ Common Stock (5,001 underlying) - Disposition to Issuer
Stock Options (Right to Buy)
2015-06-22−1,500→ 0 totalExercise: $11.35Exp: 2020-09-22→ Common Stock (1,500 underlying)
Footnotes (8)
- [F1]Pursuant to the Merger Agreement, these options, which vested 100% and became first exerciseable on July 21, 2010, accelerated, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for an amount in cash and shares of Alexion common stock equal to (i) the Transaction Consideration multiplied by (ii) a number of shares of Synageva common stock equal to (1) $230.00 minus the per share exercise price , divided by (2) $230.00, with the cash portion of such amount rounded down to the nearest cent and with the portion of such amount payable in shares of Parent common stock rounded down to the nearest one thousandth of a share. The reporting person previously transferred an option to purchase 1,375 Shares of the original 2,750 granted under this stock option, which transfer was not reported as permitted under Rule 16a-12 of the Securities Exchange Act.
- [F2]Pursuant to the Merger Agreement, these options, which vested 100% and became first exerciseable on 9/22/2011, accelerated, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for an amount in cash and shares of Alexion common stock equal to (i) the Transaction Consideration multiplied by (ii) a number of shares of Synageva common stock equal to (1) $230.00 minus the per share exercise price, divided by (2) $230.00, with the cash portion of such amount rounded down to the nearest cent and with the portion of such amount payable in shares of Parent common stock rounded down to the nearest one thousandth of a share. The reporting person previously transferred an option to purchase 1,500 Shares of the original 3,000 granted under this stock option, which transfer was not reported as permitted under Rule 16a-12 of the Securities Exchange Act.
- [F3]Pursuant to the Merger Agreement, these options, which vested 100% and became first exerciseable on June 26, 2009, accelerated, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for an amount in cash and shares of Alexion common stock equal to (i) the Transaction Consideration multiplied by (ii) a number of shares of Synageva common stock equal to (1) $230.00 minus the per share exercise price, divided by (2) $230.00, with the cash portion of such amount rounded down to the nearest cent and with the portion of such amount payable in shares of Parent common stock rounded down to the nearest one thousandth of a share. The reporting person previously transferred an option to purchase 1,375 Shares of the original 2,750 granted under this stock option, which transfer was not reported as permitted under Rule 16a-12 of the Securities Exchange Act.
- [F4]Pursuant to the Merger Agreement, these options, which vest 25% on 12/02/2011 and 1/36 of the remainder of the shares vest and become exercisable monthly thereafter, accelerated, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for an amount in cash and shares of Alexion common stock equal to (i) the Transaction Consideration multiplied by (ii) a number of shares of Synageva common stock equal to (1) $230.00 minus the per share exercise price, divided by (2) $230.00, with the cash portion of such amount rounded down to the nearest cent and with the portion of such amount payable in shares of Parent common stock rounded down to the nearest one thousandth of a share.
- [F5]Pursuant to the Merger Agreement, these options vested one-third every year over a three-year period and became exercisable on the following schedule: 33.33% on 06/27/2008, 33.33% on 06/27/2009, 33.33% on 06/27/2010, accelerated, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for an amount in cash and shares of Alexion common stock equal to (i) the Transaction Consideration multiplied by (ii) a number of shares of Synageva common stock equal to (1) $230.00 minus the per share exercise price , divided by (2) $230.00, with the cash portion of such amount rounded down to the nearest cent and with the portion of such amount payable in shares of Parent common stock rounded down to the nearest one thousandth of a share.
- [F6]Pursuant to the Merger Agreement, these options, which vest 25% on 07/06/2013 and 1/36 of the remainder of the shares vest and become exercisable monthly thereafter, accelerated, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for an amount in cash and shares of Alexion common stock equal to (i) the Transaction Consideration multiplied by (ii) a number of shares of Synageva common stock equal to (1) $230.00 minus the per share exercise price , divided by (2) $230.00, with the cash portion of such amount rounded down to the nearest cent and with the portion of such amount payable in shares of Parent common stock rounded down to the nearest one thousandth of a share. The reporting person previously transferred an option to purchase 5,001 Shares of the original 10,002 granted under this stock option, which transfer was not reported as permitted under Rule 16a-12 of the Securities Exchange Act.
- [F7]Pursuant to the Merger Agreement, these options, which vest 25% on 07/27/2012 and 1/36 of the remainder of the shares vest and become exercisable monthly thereafter, accelerated, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for an amount in cash and shares of Alexion common stock equal to (i) the Transaction Consideration multiplied by (ii) a number of shares of Synageva common stock equal to (1) $230.00 minus the per share exercise price, divided by (2) $230.00, with the cash portion of such amount rounded down to the nearest cent and with the portion of such amount payable in shares of Parent common stock rounded down to the nearest one thousandth of a share. The reporting person previously transferred an option to purchase 3.750 Shares of the original 7,500 granted under this stock option, which transfer was not reported as permitted under Rule 16a-12 of the Securities Exchange Act.
- [F8]Pursuant to the Merger Agreement, these options, which vest 25% on 07/04/2014 and 1/36 of the remainder of the shares vest and become exercisable monthly thereafter, accelerated, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for an amount in cash and shares of Alexion common stock equal to (i) the Transaction Consideration multiplied by (ii) a number of shares of Synageva common stock equal to (1) $230.00 minus the per share exercise price, divided by (2) $230.00, with the cash portion of such amount rounded down to the nearest cent and with the portion of such amount payable in shares of Parent common stock rounded down to the nearest one thousandth of a share.
Documents
Issuer
SYNAGEVA BIOPHARMA CORP
CIK 0000911326
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0000911326
Filing Metadata
- Form type
- 4
- Filed
- Jun 22, 8:00 PM ET
- Accepted
- Jun 23, 10:37 AM ET
- Size
- 27.3 KB